Article Text

Download PDFPDF
Spectral-domain optical coherence tomography in subjects over 60 years of age, and its implications for designing clinical trials

Statistics from


  • Contributors OC and CB wrote the article. PJP and CJD edited the OCT and statistical sections respectively.

  • Competing interests OC receives unrestricted research funding from Novartis. PJP has acted as a consultant for Heidelberg. CB and CJD have no competing interests.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles